Medical Cannabis Access Linked to 7% Drop in Sick Days

August 28, 2026

Photo by Mehmet Turgut Kirkgoz via Pexels.

Every HR department has some version of the same spreadsheet: a running tally of sick days, short-term disability claims, and the vague productivity hit that comes from workers showing up but not really being there. A new peer-reviewed study gives that spreadsheet an unexpected data point tied to state cannabis policy. Economists from the University of Georgia and the University of Southern Maine found that medical cannabis decriminalization is associated with a 6.9% drop in health-related work absences -- a figure that's already being rounded to 7% in headlines, but the underlying number matters because of how precisely it was measured.

The researchers didn't rely on a handful of surveys or a single state's rollout. They built their analysis on Current Population Survey data stretching from January 1990 to March 2025, covering more than 20 million workers between the ages of 18 and 61. That's roughly 35 years of state-by-state policy variation to mine, published in the Journal of Workplace Behavioral Health. The twist that's generating the most conversation among labor economists isn't the topline number -- it's that recreational legalization, on its own, showed no significant effect on absenteeism at all. Something specific about medical access, not cannabis policy broadly, appears to be doing the work.

With more than 40 states now running some form of medical cannabis program, researchers finally have enough natural policy experiments to start separating medical access from recreational legalization as distinct variables. That distinction is the whole story here.

What the Study Actually Found

Photo by Vanessa Garcia via Pexels.

The methodology matters as much as the result. The team used a flexible difference-in-differences design, a statistical approach built specifically for comparing outcomes across states that adopted a policy at different times against states that hadn't adopted it yet. Applied to monthly Current Population Survey data running from January 1990 through March 2025, it let the researchers isolate the effect of medical cannabis decriminalization from decades of other economic noise -- recessions, industry shifts, minimum wage changes, all of it.

The dataset itself is the kind labor economists dream about: over 20 million individual worker observations, ages 18 to 61, spanning more than three decades of state-level policy changes. That scale is what makes a 6.9% reduction in the likelihood of health-related absences a credible, statistically defensible finding rather than a fluke tied to one or two states.

One of the more interesting wrinkles is what didn't drive the effect. The moment a state actually decriminalized medical cannabis use produced a larger, more statistically significant drop in absences than the later moment when regulated dispensaries opened for business. In other words, legal permission to use cannabis for a medical condition mattered more than the retail infrastructure that eventually followed it. And recreational legalization, studied as its own variable, showed no significant relationship to absenteeism at all -- a distinction the authors go out of their way to highlight, since it cuts against the assumption that all cannabis liberalization produces the same workplace effects. The study started circulating publicly in mid-2026 after publication in the Journal of Workplace Behavioral Health, and that medical-versus-recreational split is the finding drawing the most attention from other researchers.

The Jobs Where the Effect Is Biggest

Fabricators/assemblers (39%) and machine operators (33%) saw far greater reductions in health-related absences than the average worker (6.9%), suggesting medical cannabis access may benefit manual labor occupations most.

Break the data down by occupation and the pattern gets a lot more specific. The biggest reductions in health-related absences showed up among workers in physically demanding jobs -- fabricators, assemblers, and manual laborers saw a 39% drop. Industrial machine operators weren't far behind, at 33%. These aren't desk-job numbers; they're the occupations most associated with repetitive strain, chronic back pain, and the kind of physical wear that accumulates over a career.

The effect wasn't confined to factory floors, either. Health service workers, farm workers, food preparation workers, and sales workers all showed meaningful declines in absenteeism tied to medical cannabis access. Look at it by industry rather than by job title and the same story holds: durable goods manufacturing, nondurable goods manufacturing, agriculture, construction, business services, and personal services all registered drops.

Put those two views together -- occupation and industry -- and a fairly coherent picture emerges. The workers benefiting most tend to be the ones doing physical labor that wears down joints, muscles, and backs over time. That lines up with the most common reason people cite for using medical cannabis in the first place: chronic pain management. The study doesn't prove causation at the individual level, but the occupational pattern is consistent enough that it's hard to write off as coincidence. Workers in labor-intensive fields losing fewer days to health issues, in states where they have legal access to cannabis for medical purposes, is exactly the kind of pattern you'd expect if cannabis access were genuinely helping people manage physical strain well enough to keep showing up.

Why Employers Should Care About the Dollar Figure

Photo by Vitaly Gariev via Unsplash.

Absenteeism isn't an abstract HR headache -- it's a line item. Patryk Babiarz, the University of Georgia economist behind the study, points to an estimated $225 billion in lost productivity that work absenteeism costs U.S. employers annually. Even a modest percentage shift against a number that large translates into real money, and Babiarz argues medical cannabis access could save hundreds of millions of dollars in economic cost simply by keeping more workers on the job rather than out sick.

That argument lands at an interesting moment for employer policy. Plenty of companies still run zero-tolerance drug testing programs that treat any cannabis metabolite the same as active impairment, regardless of whether an employee used it legally, off-hours, for a documented medical condition. HR departments in states with mature medical programs have been slowly rethinking those policies, but plenty of hesitation remains -- partly cultural, partly liability-driven, partly a holdover from testing protocols built for a pre-legalization workplace.

It's worth being precise about what this economic argument is and isn't claiming. Babiarz isn't asserting that cannabis makes people healthier in some general sense, and the study doesn't attempt to measure health outcomes at all. This is a productivity and labor-cost argument, full stop: workers with legal medical cannabis access appear to miss fewer days of work for health reasons. Whether that's because cannabis manages pain effectively, reduces reliance on other treatments with worse side effects, or something else entirely isn't something this dataset can answer. For employers deciding whether to soften drug policies, though, a dollar figure tends to move the conversation faster than a wellness argument does.

The Caveats Researchers Want You to Notice

Photo by Kindel Media via Pexels.

The authors are careful, almost pointedly so, about what their data can't tell you. They didn't examine potential negative health or behavioral outcomes tied to marijuana use -- this wasn't designed as a study of cannabis's overall health effects, positive or negative. It's a labor economics paper studying absenteeism rates against state policy timelines.

There's also a structural limit worth understanding: this is population-level data, not individual-level data. The Current Population Survey doesn't tell researchers whether a specific worker used cannabis, what medical condition they had, or whether cannabis replaced another medication they'd previously been taking. The study shows that absenteeism rates moved in states that opened medical cannabis access, aggregated across millions of workers. It doesn't show the mechanism inside any individual case.

That caution looks especially warranted next to a contrasting paper. A separate 2026 SSRN working paper by a researcher named Brown found that recreational legalization in states with active dispensaries actually increased absenteeism -- 41% more vacation and personal day absences, and 22% more medical absences, with the effect concentrated heavily among men aged 21 to 29. That's not a minor footnote; it's a direct complication to the idea that cannabis liberalization generally reduces missed work.

Read together, the two studies suggest something more nuanced than good news or bad news about cannabis and work. Medical and recreational cannabis policy may produce genuinely different workplace effects -- not simply the same effect at different intensities. A middle-aged worker managing chronic pain under a medical program looks like a very different case than a 24-year-old with easy recreational access to a dispensary, and the data seems to be picking up exactly that kind of divergence.

What This Means Going Forward

Photo by Patrik Felker via Pexels.

The policy landscape underneath all this keeps shifting. More than 40 states now run medical cannabis programs, and that number keeps growing, which means researchers and employers alike have an expanding real-world dataset to draw from -- decades of natural experiments happening state by state rather than in a lab.

None of that changes the practical reality that legality and workplace drug policy still vary enormously depending on where you live and who you work for. A medical cannabis card that offers real workplace protections in one state may mean almost nothing in another, and individual employers -- especially larger companies with standardized national HR policies -- often set rules well beyond what state law requires. Readers weighing any of this against their own job situation should confirm current local law and their employer's actual written policy rather than assuming a study like this changes anything on the ground.

Federal law adds another layer of friction. Cannabis remains a Schedule I substance federally, and employers with federal contracts or federal funding often have little choice but to maintain strict testing and use policies regardless of what their state's medical program allows. That mismatch between state medical access and federal illegality isn't going away because of one labor economics paper, however compelling its numbers are.

What this study does is add real weight to the economic case for medical cannabis access -- weight built on 35 years of labor data rather than advocacy talking points. But it sits alongside a countervailing finding on recreational use that complicates any tidy narrative. This is one solid data point in a research area that's still very much in motion, not a closing argument.

Most cannabis policy debates get argued in broad strokes -- legal versus illegal, decriminalized versus not. This research draws a much sharper line: it's medical access specifically, not cannabis legalization in general, that tracks with fewer missed workdays. Recreational legalization, studied on its own, didn't move the needle on absenteeism at all, and a separate paper suggests it might even push absences up among younger workers. That's not a contradiction so much as evidence that medical and recreational cannabis policy are functioning as genuinely different interventions with different populations and different effects.

For employers still treating cannabis-friendly HR policy as a cultural or liability question rather than a financial one, this study reframes the conversation. The productivity argument now has 35 years of labor data behind it instead of anecdotes from individual companies that loosened their testing policies. That doesn't mean every business should rewrite its drug policy tomorrow, but it does mean the old assumption -- that accommodating medical cannabis use is purely a risk with no offsetting benefit -- is getting harder to defend on the numbers alone.

Expect more research in this vein as states keep tweaking both medical and recreational frameworks and as more longitudinal data becomes available. This study is a solid, well-constructed data point, not a final verdict. Anyone making decisions based on it -- whether as an employer, an HR policy writer, or an employee wondering what protections actually apply to them -- should treat it as one piece of a still-developing picture and check the specifics of their own state's law before assuming anything.